229 related articles for article (PubMed ID: 20104222)
1. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis.
Cella D; Michaelson MD; Bushmakin AG; Cappelleri JC; Charbonneau C; Kim ST; Li JZ; Motzer RJ
Br J Cancer; 2010 Feb; 102(4):658-64. PubMed ID: 20104222
[TBL] [Abstract][Full Text] [Related]
2. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.
Cella D; Li JZ; Cappelleri JC; Bushmakin A; Charbonneau C; Kim ST; Chen I; Motzer RJ
J Clin Oncol; 2008 Aug; 26(22):3763-9. PubMed ID: 18669464
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population.
Castellano D; del Muro XG; Pérez-Gracia JL; González-Larriba JL; Abrio MV; Ruiz MA; Pardo A; Guzmán C; Cerezo SD; Grande E
Ann Oncol; 2009 Nov; 20(11):1803-12. PubMed ID: 19549706
[TBL] [Abstract][Full Text] [Related]
4. Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma.
Cella D; Bushmakin AG; Cappelleri JC; Charbonneau C; Michaelson MD; Motzer RJ
Br J Cancer; 2012 Feb; 106(4):646-50. PubMed ID: 22240794
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
Cella D; Motzer RJ; Suarez C; Blum SI; Ejzykowicz F; Hamilton M; Wallace JF; Simsek B; Zhang J; Ivanescu C; Apolo AB; Choueiri TK
Lancet Oncol; 2022 Feb; 23(2):292-303. PubMed ID: 35032437
[TBL] [Abstract][Full Text] [Related]
6. Using the Rasch model to validate and enhance the interpretation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index--Disease-Related Symptoms scale.
Luo X; Cappelleri JC; Cella D; Li JZ; Charbonneau C; Kim ST; Chen I; Motzer RJ
Value Health; 2009 Jun; 12(4):580-6. PubMed ID: 19900256
[TBL] [Abstract][Full Text] [Related]
7. Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.
Cella D; Davis MP; Négrier S; Figlin RA; Michaelson MD; Bushmakin AG; Cappelleri JC; Sandin R; Korytowsky B; Charbonneau C; Matczak E; Motzer RJ
Cancer; 2014 Jun; 120(12):1871-80. PubMed ID: 24634003
[TBL] [Abstract][Full Text] [Related]
8. Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma.
Cella D; Motzer RJ; Rini BI; Cappelleri JC; Ramaswamy K; Hariharan S; Arondekar B; Bushmakin AG
Value Health; 2018 Dec; 21(12):1413-1418. PubMed ID: 30502785
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Motzer R; Porta C; Alekseev B; Rha SY; Choueiri TK; Mendez-Vidal MJ; Hong SH; Kapoor A; Goh JC; Eto M; Bennett L; Wang J; Pan JJ; Saretsky TL; Perini RF; He CS; Mody K; Cella D
Lancet Oncol; 2022 Jun; 23(6):768-780. PubMed ID: 35489363
[TBL] [Abstract][Full Text] [Related]
10. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
Harmon CS; DePrimo SE; Figlin RA; Hudes GR; Hutson TE; Michaelson MD; Négrier S; Kim ST; Huang X; Williams JA; Eisen T; Motzer RJ
Cancer Chemother Pharmacol; 2014 Jan; 73(1):151-61. PubMed ID: 24220935
[TBL] [Abstract][Full Text] [Related]
11. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.
Cella D; Grünwald V; Nathan P; Doan J; Dastani H; Taylor F; Bennett B; DeRosa M; Berry S; Broglio K; Berghorn E; Motzer RJ
Lancet Oncol; 2016 Jul; 17(7):994-1003. PubMed ID: 27283863
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
Cella D; Grünwald V; Escudier B; Hammers HJ; George S; Nathan P; Grimm MO; Rini BI; Doan J; Ivanescu C; Paty J; Mekan S; Motzer RJ
Lancet Oncol; 2019 Feb; 20(2):297-310. PubMed ID: 30658932
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Motzer RJ; Hutson TE; Tomczak P; Michaelson MD; Bukowski RM; Rixe O; Oudard S; Negrier S; Szczylik C; Kim ST; Chen I; Bycott PW; Baum CM; Figlin RA
N Engl J Med; 2007 Jan; 356(2):115-24. PubMed ID: 17215529
[TBL] [Abstract][Full Text] [Related]
14. Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α.
Patil S; Figlin RA; Hutson TE; Michaelson MD; Negrier S; Kim ST; Huang X; Motzer RJ
Br J Cancer; 2012 May; 106(10):1587-90. PubMed ID: 22568998
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Tsimafeyeu I; Zart JS; Chung B
BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
[TBL] [Abstract][Full Text] [Related]
16. Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.
Bedke J; Rini BI; Plimack ER; Stus V; Gafanov R; Waddell T; Nosov D; Pouliot F; Soulières D; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Tamada S; Nguyen AM; Wan S; Perini RF; Rhoda Molife L; Atkins MB; Powles T
Eur Urol; 2022 Oct; 82(4):427-439. PubMed ID: 35843776
[TBL] [Abstract][Full Text] [Related]
17. Commentary on "Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α." Tsimafeyeu I, Zart JS, Chung B, Kidney Cancer Research Bureau, Moscow, Russian Federation.: BJU Int 2013; 112(1):32-8. [Epub 2013 Jun 7]. doi: 10.1111/bju.12107.
Boorjian S
Urol Oncol; 2014 May; 32(4):514-5. PubMed ID: 24767689
[TBL] [Abstract][Full Text] [Related]
18. [A Cost-effectiveness Analysis of Sunitinib vs. Interferon-alpha in Patient with Advanced Renal Cell Carcinoma in Japan].
Tomura K; Naito Y; Sunaga T; Kurihara T; Usuda M; Nagatani A; Ogawa Y; Akiyama N; Sasaki H; Murata T; Sakamaki H; Kogo M; Sasaki T
Yakugaku Zasshi; 2018; 138(11):1397-1407. PubMed ID: 30381648
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma.
Remák E; Charbonneau C; Négrier S; Kim ST; Motzer RJ
J Clin Oncol; 2008 Aug; 26(24):3995-4000. PubMed ID: 18711190
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha.
Dirican A; Kucukzeybek Y; Erten C; Somali I; Demir L; Can A; Payzin KB; Bayoglu IV; Akyol M; Yildiz Y; Koeseoglu M; Alacacioglu A; Tarhan MO
Asian Pac J Cancer Prev; 2013; 14(3):2101-5. PubMed ID: 23679326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
